Skip to main content
SpringerLink
Log in

Current and Investigational Drugs for the Prevention of Migraine in Adults and Children

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

There are only a handful of drugs that have been submitted for and received an indication for the preventative treatment of migraine by the US Food and Drug Administration, as well as international governmental regulatory agencies. However, there are a wide variety of agents that are used for this indication with different levels of evidence for efficacy and tolerability. Several guidelines have been published in recent years examining the evidence-based medicine of migraine preventative therapy and these provide guidance especially for the primary care clinician, but also for neurologists whose primary focus is not headache medicine. Some of the therapies are used in children and adolescents while others are used more commonly in adults. In the adult population, an evolutive state of migraine is more commonly seen than in young persons, that is chronic migraine. There is a paucity of evidence for medications for this stage of migraine but there is a single agent that is approved for this use but not for use in the treatment of episodic migraine. There have been few advances in the field of migraine-preventative medications in recent years but potential novel approaches are in development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. New restrictions on use of medicines containing ergot derivatives. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001832.jsp&mid=WC0b01ac058004d5c1. Accessed 2 June 2014.

  2. Lipton R, Bigal M, Diamond ML, Freitag FG, Reed M, Stewart W. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.

    Article  PubMed  CAS  Google Scholar 

  3. Forssman B, Henriksson KG, Johannsson V, Lindvall L, Lundin H. Propranolol for migraine prophylaxis. Headache. 1976;16(5):238–45.

    Article  PubMed  CAS  Google Scholar 

  4. Pradalier A, Serratrice G, Collard M, Hirsch E, Feve J, Masson M, Masson C, Dry J, Koulikovsky G, Nguyen G, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9(4):247–53.

    Article  PubMed  CAS  Google Scholar 

  5. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337–45.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol: a double-blind crossover study. JAMA. 1984;252(18):2576–80.

    Article  PubMed  CAS  Google Scholar 

  7. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):186–281.

    Article  Google Scholar 

  8. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12(2):81–4.

    Article  PubMed  CAS  Google Scholar 

  9. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652–9.

    Article  PubMed  CAS  Google Scholar 

  10. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968–75.

    Article  PubMed  CAS  Google Scholar 

  11. Brandes JL, Saper JR, Diamond M, MIGR-002 Study Group, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–73.

    Article  PubMed  CAS  Google Scholar 

  12. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49:1153–62.

    Article  PubMed  Google Scholar 

  13. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS, European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.

    Article  PubMed  CAS  Google Scholar 

  14. Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, Gladstone J, Becker WJ, Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1–59.

    PubMed  Google Scholar 

  15. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47(4):486–99.

    PubMed  Google Scholar 

  16. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JM, Turkel C. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26(7):790–800.

    Article  PubMed  CAS  Google Scholar 

  17. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1–2):48–56.

    Article  PubMed  CAS  Google Scholar 

  18. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.

    Article  PubMed  CAS  Google Scholar 

  19. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.

    Article  PubMed  CAS  Google Scholar 

  20. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21–32.

    Article  PubMed  Google Scholar 

  21. Kabbouche M, O’Brien H, Hershey AD. OnabotulinumtoxinA in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012;12(2):114–7.

    Article  PubMed  CAS  Google Scholar 

  22. Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs. 2009;41(5):235–43.

    Article  PubMed  Google Scholar 

  23. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78:1346–53.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28(1):15–23.

    Article  PubMed  CAS  Google Scholar 

  25. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN, de FineOlivarius B. Prophylactic treatment of classical and non-classical migraine with metoprolol: a comparison with placebo. Cephalalgia. 1983;3(4):207–12.

    Article  PubMed  CAS  Google Scholar 

  26. Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63(12):2240–4.

    Article  PubMed  CAS  Google Scholar 

  27. Grossman W, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern Med Rev. 2001;6(3):303–10.

    PubMed  CAS  Google Scholar 

  28. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache. 2003;43(1):76–8.

    Article  PubMed  Google Scholar 

  29. Prieto JM. Update on the efficacy and safety of Petadolex®, a butterbur extract for migraine prophylaxis. Bot Targ Ther. 2014;4:1–9.

    Article  Google Scholar 

  30. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version. Cephalalgia. 2013;33(9):734.

    Article  Google Scholar 

  31. Papetti L, Spalice A, Nicita F, Paolino MC, Castaldo R, Iannetti P, Villa MP, Parisi P. Migraine treatment in developmental age: guidelines update. J Headache Pain. 2010;11:267–76.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rao BS1, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48(3):223–632. http://clinicaltrials.gov/show/NCT01688739. Accessed 2 June 2014 Ascending Single Doses of AMG 334 in Healthy Subjects and Migraine Patients.

  33. Escandon R, Bronson M, Walter S, Bigal M. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Neurology. 2014;82(10 Suppl):P7–190.

    Google Scholar 

  34. Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of enalapril in migraine prophylaxis: a randomized double-blind, placebo-controlled trial. Int J Prev Med. 2013;4(1):72–7.

    PubMed  PubMed Central  Google Scholar 

  35. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.

    Article  PubMed  CAS  Google Scholar 

  36. Zandifar A, Masjedi SS, Banihashemi M, Asgari F, Manoucherhri N, Ebrahimi H, Haghdoost F, Saadatnia M. Vitamin D status in migraine patients: a case control study. BioMed Res Int. 2014;2014:514782.

    PubMed  PubMed Central  Google Scholar 

  37. Srinivasan V, Lauterbach EC, Ho KY, Acuña-Castroviejo D, Zakaria R, Brzezinski A. Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol. 2012;10(2):167–78.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Peres MF, Zukerman E, da CunhaTanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004;63(4):757.

    Article  PubMed  CAS  Google Scholar 

  39. Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010;75(17):1527–32.

    Article  PubMed  CAS  Google Scholar 

  40. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for migraine management: agomelatine. Clin Neuropharmacol. 2013;36(2):65–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

Dr. Freitag is a consultant to Avinar Pharmaceuticals and Biohealthonomics. He has conducted clinical research for Amgen Pharmaceuticals. He has received no financial support for the writing of this article. Dr. Shumate has nothing to disclose.

Author information

Authors and Affiliations

  1. Department of Neurology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI, 53226, USA

    Frederick G. Freitag & Derrick Shumate

Authors
  1. Frederick G. Freitag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derrick Shumate
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frederick G. Freitag.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freitag, F.G., Shumate, D. Current and Investigational Drugs for the Prevention of Migraine in Adults and Children. CNS Drugs 28, 921–927 (2014). https://doi.org/10.1007/s40263-014-0202-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0202-2

Keywords

Search

Navigation